Re­gen­eron, Sanofi rack up a PhI­II asth­ma win for dupilum­ab; Ve­rastem preps FDA app for du­velis­ib

Re­gen­eron and Sanofi say their tri­al of Dupix­ent (dupilum­ab) hit the pri­ma­ry and key sec­ondary end­points in a Phase III asth­ma study. Their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.